Pages that link to "Q79522451"
Jump to navigation
Jump to search
The following pages link to Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome (Q79522451):
Displaying 50 items.
- Current and emerging therapies in unresectable and recurrent gastric cancer (Q26745453) (← links)
- Potential biomarkers for esophageal cancer (Q26749416) (← links)
- Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer (Q26753864) (← links)
- Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction (Q27026253) (← links)
- Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma (Q28085367) (← links)
- Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer (Q30436049) (← links)
- Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma (Q33592904) (← links)
- Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer (Q33712400) (← links)
- Biologic therapy in esophageal and gastric malignancies: current therapies and future directions (Q33895597) (← links)
- Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy (Q33932460) (← links)
- Neoadjuvant treatment of esophageal cancer (Q34063710) (← links)
- Biomarkers in Barrett’s esophagus and esophageal adenocarcinoma: Predictors of progression and prognosis (Q34385125) (← links)
- O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer (Q34390612) (← links)
- Current status of novel agents in advanced gastroesophageal adenocarcinoma (Q34962039) (← links)
- A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus (Q35050662) (← links)
- The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. (Q35065408) (← links)
- Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair (Q35142705) (← links)
- Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction (Q35208151) (← links)
- A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma (Q35667892) (← links)
- Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy (Q35835137) (← links)
- Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence (Q35970960) (← links)
- Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation (Q36022348) (← links)
- Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma (Q36027475) (← links)
- Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy (Q36076031) (← links)
- High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. (Q36210986) (← links)
- Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma (Q36547753) (← links)
- Biologics in combination with chemotherapy for gastric cancer: is this the answer? (Q36551870) (← links)
- Color-matched and fluorescence-labeled esophagus phantom and its applications (Q36602406) (← links)
- Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy (Q36654970) (← links)
- Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer (Q36714384) (← links)
- GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers? (Q36737638) (← links)
- Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial (Q36801223) (← links)
- Last line therapy with sorafenib in colorectal cancer: A retrospective analysis (Q37014304) (← links)
- Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies (Q37038482) (← links)
- Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin (Q37081037) (← links)
- Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer (Q37121410) (← links)
- Chemoradiotherapy for esophageal cancer. (Q37198622) (← links)
- ErbB receptors in the biology and pathology of the aerodigestive tract (Q37263452) (← links)
- Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma (Q37269426) (← links)
- ERBBs in the gastrointestinal tract: recent progress and new perspectives (Q37337542) (← links)
- The progress of targeted therapy in advanced gastric cancer (Q37427269) (← links)
- Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy (Q37652493) (← links)
- The Pathogenesis of Barrett’s Metaplasia and the Progression to Esophageal Adenocarcinoma (Q37777076) (← links)
- Targeting the human EGFR family in esophagogastric cancer (Q37862077) (← links)
- Molecular targeted agents for gastric and gastroesophageal junction cancer (Q37962816) (← links)
- Current developments in the management of locally advanced esophageal cancer (Q38006438) (← links)
- Multi-modality therapy for cancer of the esophagus and GE junction (Q38010632) (← links)
- Multidisciplinary approach for patients with esophageal cancer (Q38067386) (← links)
- Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. (Q38161727) (← links)
- Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. (Q38385570) (← links)